The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Invitae plans to raise $50 million through a secondary common stock. As usual, the underwriters of the deal are also being granted an option to purchase up to an additional $7.5 million worth of stock ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Adria Cimino: It's true Invitae has struggled to turn revenue gains into profit. But it made a move in July that may have put it on the right path. The company launched a strategic business ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

April 16 (Reuters) - The U.S. Department of Justice's bankruptcy watchdog said on Monday that genetic test maker Invitae Corp should not be allowed to hire Kirkland & Ellis as bankruptcy counsel ...

Feb 13 (Reuters) - Softbank-backed (9434.T), opens new tab genetic test maker Invitae (NVTA.PK), opens new tab said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...

Invitae(NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and Drug ...